[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-tumor":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100506190","longitudinal-prospective-french-multicenter-cohort-study-on-pancreatic-radiofrequency-100506190",false,"NCT05871164","Longitudinal, Prospective, French, Multicenter Cohort Study on Pancreatic Radiofrequency","RAFPAN2","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* Patient to be treated for a pancreatic tumor by ultrasound-guided RF with a fine needle;\n* Indication of pancreatic radiofrequency validated in a Multidisciplinary Consultation Meeting;\n* Patient able to understand the information related to the study;\n* Patient accepting study follow-up visits;\n* Patient having been informed and agreeing to participate in the study.\n\nExclusion Criteria:\n\n* Patient with a contraindication to radiofrequency treatment;\n* Pregnant or breastfeeding women","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","The purpose of the study is to evaluate the oncological efficacy of pancreatic radiofrequency by the objective response rate (complete and partial responses according to RECIST 1.1.), 5 years after the end of treatment.",[24],"Pancreatic Tumor","RECRUITING","2026-03-27",{"date":28,"type":29},"2026-04-01","ACTUAL",{"date":31,"type":29},"2023-06-12",{"date":33,"type":20},"2030-05",{"name":35,"class":36},"GCS Ramsay Santé pour l'Enseignement et la Recherche","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":48,"studyType":21,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100368284","the-momentum-study-the-multiple-outcome-evaluation-of-radiation-therapy-using-the-mr-linac-study-100368284","NCT04075305","The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","MOMENTUM","Inclusion Criteria:\n\n* Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;\n* Patient provides written, informed consent;\n* Patient is 18 years old or older.\n\nExclusion Criteria:\n\n* MRI exclusion criteria, including\n* MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.",{"count":47,"type":20},8000,"2 Years","The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.",[51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,24,76,77,78,79,80,81,82,83,84,85,86,87],"Oncology","Breast Cancer","Prostate Cancer","Gynecologic Cancer","Brain Tumor","Brain Cancer","Gynecologic Tumor","Prostate Tumor","Prostate Neoplasm","Breast Tumor","Radiation Toxicity","Quality of Life","Rectal Cancer","Rectal Tumor","Rectal Neoplasms","Lung Cancer","Lung Tumor","Lung Neoplasm","Esophageal Cancer","Esophagus Cancer","Esophageal Tumor","Esophageal Neoplasm","Esophagus Tumor","Esophagus Neoplasm","Pancreatic Cancer","Pancreatic Neoplasms","Head and Neck Cancer","Head and Neck Neoplasms","Head and Neck Tumor","Tumor","Neoplasms","Bladder Cancer","Bladder Neoplasm","Liver Cancer","Liver Neoplasms","Liver Metastases","Oligometastases","2026-03-03",{"date":90,"type":29},"2026-03-05",{"date":92,"type":29},"2019-02-01",{"date":94,"type":20},"2030-08-01",{"name":96,"class":36},"UMC Utrecht",18,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":37},"100500268","metabolic-profile-of-hepatocarcinoma-and-pancreatic-tumors-100500268","NCT05794048","METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors","PROMETHEP","Inclusion criteria :\n\nCommon criteria:\n\n* Patient aged 18 or over\n* Informed and having signed the consent to participate\n* Affiliated with a social security scheme or entitled\n\n  1- Patients with hepatocellular carcinoma\n* Having a HCC eligible for surgical treatment (liver resection or liver transplantation) not requiring preoperative anti-tumor treatment as validated by the multidisciplinary consultation meeting for primary hepatic tumors\n* OR having a HCC not eligible for curative treatment (liver resection, liver transplantation, tumor ablation), as validated by the multidisciplinary consultation meeting for primary hepatic tumors 2- Patients with pancreatic adenocarcinoma or pancreatic neuroendocrine tumor\n* Having ADKP or NET eligible for surgical treatment (duodenopancreatectomy, left pancreatectomy, enucleation, central pancreatectomy, hepatic metastasectomy) with or without preoperative anti-tumor treatment as validated by the multidisciplinary consultation meeting.\n* OR with an unresectable ADKP or TNEP, with only medical treatment plan as validated by the multidisciplinary consultation meeting\n\nExclusion criteria :\n\nCriteria common to all patients:\n\n* Pregnancy and lactation\n* Lack of informed, written and signed consent\n* Adult person subject to a legal protection measure or unable to express consent\n* Patient under State Medical Aid (AME)\n* Person deprived of liberty by a judicial or administrative decision\n* Person undergoing psychiatric care\n\n  1- Patients with hepatocellular carcinoma\n* Suspicion of mixed tumor (hepatocholangiocarcinoma) or intrahepatic cholangiocarcinoma\n* History of systemic or locoregional anti-tumor treatment in the target tumor\n* Contraindication to a liver biopsy\n* Decompensated cirrhosis 2- Patients with pancreatic adenocarcinoma or pancreatic neuroendocrine tumor\n* Suspicion of mixed tumor (MINEN) or intra-pancreatic cholangiocarcinoma\n* Contraindication to a pancreatic \u002F hepatic biopsy",{"count":106,"type":20},300,"INTERVENTIONAL",[109],"NA","Hepatic (hepatocellular carcinoma (HCC)) and pancreatic (pancreatic adenocarcinoma (ADKP); pancreatic neuroendocrine tumors (TNEP)) primary tumors are the most common malignant tumors of the hepato-bilio-pancreatic system and represent a major public health issue. At present, the management of these tumors is based on recommendations based on the existence of rudimentary prognostic and theranostics markers that do not sufficiently accurately reflect the heterogeneity of tumor biology. It therefore seems essential to identify new and more relevant markers in order to optimize the care of these patients in daily practice.\n\nMetabolic reprogramming is now recognized as an essential feature of cancer cells, allowing them to fuel and maintain their proliferation and tumor growth. Such metabolic reprogramming requires modification of several energy pathways, the most commonly recognized being the transition from energy metabolism based on oxidative phosphorylation to energy metabolism based on glycolysis, even under aerobic conditions (Warburg effect). In this context, the investigators hypothesized that the consumption of nutrients by the tumor cell differs significantly from that of the normal cell in order to support its increased energy needs, and that this important and specific metabolic reprogramming would be correlated with the histo-prognostic and theranostics factors of these tumors. Preliminary analyses on surgical resection parts conducted by the various partners in 2019 made it possible to characterize the metabolic signatures of a series of HCC and ADKP resected using the Metafora biosystems technology platform. These signatures reflect a metabolic program characteristic of these tumors, which reveal strong specificities. Similarly, a candidate signature correlating with the presence of vascular microscopic invasion has been identified in HCC, and the level of activation of glycolysis and glutaminolysis by certain ADKP cells also appears as a trait of interest vis-à-vis the aggressiveness of this cancer.\n\nThus, the current project will aim to confirm the feasibility of identifying specific prognostic and theranostics metabolic signatures early, on biopsy samples and \u002F or circulating blood cells.",[112,24],"Hepatocarcinoma",[112,24],"2024-02-06",{"date":116,"type":29},"2024-02-07",{"date":118,"type":29},"2022-06-08",{"date":120,"type":20},"2026-09-08",{"name":122,"class":36},"Assistance Publique - Hôpitaux de Paris"]